Revolution Medicines (RVMD) Operating Leases (2020 - 2026)

Revolution Medicines' Operating Leases history runs 7 years deep, the most recent figure standing at $140.0 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 15.37% year-over-year to $140.0 million in Q1 2026; TTM through Mar 2026 was $140.0 million, a 15.37% increase from a year earlier, with the FY2025 full-year figure at $142.2 million, up 15.66% from the prior year.
• Operating Leases fell to $140.0 million in Q1 2026 per RVMD's latest filing, from $142.2 million in the prior quarter.
• Across five years, Operating Leases topped out at $142.2 million in Q4 2025 and bottomed at $57.1 million in Q3 2023.
• The 5-year median for Operating Leases is $79.1 million (2024), against an average of $89.0 million.
• Biggest YoY gain for Operating Leases was 116.88% in 2022; the steepest drop was 4.94% in 2022.
• Year by year, Operating Leases stood at $57.4 million in 2022, then surged by 40.3% to $80.6 million in 2023, then surged by 52.62% to $123.0 million in 2024, then grew by 15.66% to $142.2 million in 2025, then decreased by 1.56% to $140.0 million in 2026.
• Per Business Quant, the three latest RVMD Operating Leases figures stand at $140.0 million (Q1 2026), $142.2 million (Q4 2025), and $142.1 million (Q3 2025).